ArticleFrontiers in bioengineering and biotechnology2020
Improved Prodigiosin Production by Relieving CpxR Temperature-Sensitive Inhibition.
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Regulatory role of the Cpx ESR in bacterial behaviours.Virulence · 2024Review
- Serratia marcescens ATCC 274 increases production of the red pigment prodigiosin in response to Chi phage infection.Scientific reports · 2024Article
- Pigments from pathogenic bacteria: a comprehensive update on recent advances.World journal of microbiology & biotechnology · 2024Review
- Investigating the Role of OrbF in Biofilm Biosynthesis and Regulation of Biofilm-Associated Genes inFoods (Basel, Switzerland) · 2024Article
- Prodigiosin: unveiling the crimson wonder - a comprehensive journey from diverse bioactivity to synthesis and yield enhancement.Frontiers in microbiology · 2024Review
- Isolation and Characterization of aMarine drugs · 2023Article
- A comprehensive profiling of quorum quenching by bacterial pigments identifies quorum sensing inhibition and antibiofilm action of prodigiosin against Acinetobacter baumannii.Archives of microbiology · 2023Article
- Article
- Article
- Recent Advances in Prodigiosin as a Bioactive Compound in Nanocomposite Applications.Molecules (Basel, Switzerland) · 2022Review
- Prodigiosin: a promising biomolecule with many potential biomedical applications.Bioengineered · 2022Review
- Improving prodigiosin production by transcription factor engineering and promoter engineering inFrontiers in microbiology · 2022Article
- Enhanced Prodigiosin Production inApplied and environmental microbiology · 2021Article
- Antibiotics Used in Empiric Treatment of Ocular Infections Trigger the Bacterial Rcs Stress Response System Independent of Antibiotic Susceptibility.Antibiotics (Basel, Switzerland) · 2021Article
- Identification of Essential Genes Associated With Prodigiosin Production inFrontiers in microbiology · 2021Article
- Transcriptomic Analysis Reveals Competitive Growth Advantage of Non-pigmentedFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prodigiosin (PG) is a typical secondary metabolite mainly produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.